Teva Fights To Invalidate Bayer Patent Over Testosterone Drug

By Lucia Osborne-Crowley (January 12, 2022, 7:52 PM GMT) -- Generic-drug maker Teva Pharmaceuticals is suing rival Bayer to invalidate its patent over a testosterone supplement, arguing that the injectable hormone treatment is not inventive or novel.

Israel-based Teva Pharmaceutical Industries Ltd. tells the High Court in a Dec. 22 claim just made public that a patent held by Bayer Schering Pharma AG is invalid and should not be enforced.

The generic-drug maker argued that Bayer's patent over an injectable steroid product used to treat low testosterone levels is invalid because the drug already existed and the German firm's version contains no so-called inventive step. Drug firms must prove they applied...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!